Demographic data | |
Numbers of patients | 477 |
Gender, male/female, n | 282/195 |
Age, year* | 53 (20–87) |
Body mass index, kg/m2* | 26.3 (16.6–42.4) |
Waist circumference, cm* | 91.3 (68.2–132.1) |
Smoking, absence/presence, n | 385 /92 |
Previous or current events | |
Cardiovascular diseases, absence/presence/unknown, n | 444/30/3 |
Malignancies, except for liver cancer, absence/presence/unknown, n | 426/47/4 |
Liver-related events, absence/presence/unknown, n | 432/42/3 |
Liver cancer, absence/presence/unknown, n | 446/30/1 |
Ascites, absence/presence/unknown, n | 472/2/3 |
Hepatic encephalopathy, absence/presence/unknown, n | 474/0/3 |
Jaundice, absence/presence/unknown, n | 471/3/3 |
Esophago-gastric varices, absence/presence/unknown, n | 463/11/3 |
Comorbid diseases | |
Type 2 diabetes mellitus, absence/presence, n | 321/156 |
Hypertension, absence/presence, n | 256/221 |
Dyslipidemia, absence/presence, n | 125/352 |
Hyperuricemia, absence/presence, n | 420/57 |
Chronic kidney disease, absence/presence, n | 445/32 |
Histological findings | |
Steatosis, 5–33%/ > 33–66%/ > 66%, n | 174/175/126 |
Lobular inflammation | |
No foci/< 2 foci/2–4 foci/> 4 foci per 200 × field, n | 28/263/167/17 |
Ballooning, none/few cells/many cells, n | 42/298/135 |
Fibrosis stage, 0/1/2/3/4, n | 55/189/77/121/35 |
NAFLD activity score, ≤ 2/3/4/ ≥ 5, n | 38/197/242 |
Genetic factors | |
PNPLA3 rs738409 (CC/CG/GG/Not determined) | 57/137/135/148 |
TM6SF2 rs58542926 (CC/CT/TT/Not determined) | 248/74/7/148 |
ALDH2 rs671 (GG/GA/AA/Not determined) | 158/142/29/148 |
HSD17B13 rs6834314 (AA/AG/GG/Not determined) | 162/132/25/158 |
Laaboratory dataa | |
Serum aspartate aminotransferase (AST), U/L | 44 (3–378) |
Serum alanine aminotransferase (ALT), U/L | 69 (13–783) |
Gamma-glutamyl transpeptidase, U/L | 71 (11–1,135) |
Platelet count, × 103/mm3 | 212 (40–471) |
Albumin | 4.1 (2.8–6.9) |
Serum ferritin, μg/L | 227 (< 10–2.067) |
High sensitive C-reactive protein, mg/dL | 0.097 (0.004–2.240) |
FIB-4 index | 1.36 (0.19–14.8) |